Initial Experience of Pacing with a Lumenless Lead System in Patients with Congenital Heart Disease

S Chakrabarti, GJ Morgan, D Kenny, KP Walsh, P Oslizlok, RP Martin, MS Turner, AG Stuart

Research output: Contribution to journalArticle (Academic Journal)peer-review

10 Citations (Scopus)

Abstract

Background: Long-term pacing is frequently necessary in patients with congenital heart disease (CHD). Preservation of ventricular function and avoidance of venous occlusion is important in these patients. Site-selective pacing with a smaller diameter lead is achievable with the model 3830 lead (SelectSecure(R), Medtronic Inc., Minneapolis, MN, USA), which was specifically designed to target these complications. We describe our initial experience with the Model 3830 lead in patients with CHD. Methods: Retrospective analysis of all patients undergoing site-selective implantation of a Model 3830 lead(s) from two congenital heart centers (Bristol, UK, and Dublin, Ireland) from October 2004 until February 2008. Results: We implanted 139 SelectSecure(R) leads (atrial n = 70; ventricular n = 69) in 90 patients (57 male) with CHD. Median age at implantation: 13.4 years (1.1-59.2 years), median weight: 43 kg. Sixty-nine patients (76%) were children (
Translated title of the contributionInitial Experience of Pacing with a Lumenless Lead System in Patients with Congenital Heart Disease
Original languageEnglish
Pages (from-to)1428 - 1433
Number of pages6
JournalPacing and Clinical Electrophysiology
Volume32(11)
Publication statusPublished - Nov 2009

Bibliographical note

Publisher: Wiley

Fingerprint Dive into the research topics of 'Initial Experience of Pacing with a Lumenless Lead System in Patients with Congenital Heart Disease'. Together they form a unique fingerprint.

Cite this